Assays
Within this product group you will find many: ELISAs, ELISPOTs, protein detection assays, and many more assays.
PCR | B- & T-cell clonality assays (IGH, IGK, TRG, TRB) | Chromosome Translocations | CDx FLT3 Mutation Assay | NGS Gene Panels | MRD clonality solutions | Molecular Biology | Services for Oncology Testing
Invivoscribe® is a global technology-driven cancer diagnostics company. Our mission is to optimize patient care and accelerate drug approvals worldwide by providing best-in-class products and services.
Invivoscribe provides a comprehensive selection of PCR-based products, including B- & T-cell clonality assays (IGH, IGK, TRG, TRB), chromosome translocations, the LeukoStrat® CDx FLT3 Mutation Assay, NGS gene panels and minimal residual disease (MRD) solutions with bioinformatics software.
Invivoscribe solutions are available as research use only testing reagents and controls as well as CE-marked in vitro diagnostic products.
Improving Lives with Precision Diagnostics®
Bio-Connect supplies all their products in the Benelux. If you have any questions, please contact the helpdesk.
Invivoscribe’s assays inform and guide the patient’s physician from diagnosis through the entire course of therapy.
Molecular Biology
Molecular Biology
Molecular Biology
Molecular Biology
Molecular Biology
Labware / Accesories
Labware / Accesories
Labware / Accesories
Proteins / Signaling Molecules
Molecular Biology
Molecular Biology
Assays
Assays
Assays
Assays
Assays
Assays
Assays
Assays
Molecular Biology
Molecular Biology
Molecular Biology
Molecular Biology
Molecular Biology
Molecular Biology
Illumina® Performance Comparison of Invivoscribe’s LymphoTrack® Assays Between Complete Genomics DNBSEQ-G99 and NGS Platforms MiSeqTM
pdf
Clonality and Measurable Residual Disease (MRD) Testing on the Illumina® NextSeqTM Sequencers
pdf
Comparison of Complete Genomics DNBSEQ-G99 Sequencer and Illumina® MiSeqTM using Invivoscribe’s FLT3 ITD MRD Assay and NPM1 MRD Assay
pdf
Ha J, Lee H, Shin S, et al. Ig gene clonality analysis using next-generation sequencing for improved minimal residual disease detection with significant prognostic value in multiple myeloma patients.
Ho C, Syed M, Roshal M, et al. Routine evaluation of minimal residual disease in myeloma using next-generation sequencing clonality testing: feasibility, challenges, and direct comparison with high-sensitivity flow cytometry.
Kadkol SS, Bland J, Kavanaugh A, Ni H, Nehru V, Peace D. Ngs analysis of clonality and minimal residual disease in a patient with concurrent richter’s transformation and cll/sll.
Kim M, Jeon K, Hutt K, et al. Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing.
Ho CC, Tung JK, Zehnder JL, Zhang BM. Validation of a next-generation sequencing-based t-cell receptor gamma gene rearrangement diagnostic assay: transitioning from capillary electrophoresis to next-generation sequencing.
Cheng S, Inghirami G, Cheng S, Tam W. Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL.
Stamatopoulos B, Timbs A, Bruce D, et al. Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia.
Levis MJ, Perl AE, Altman JK, et al. A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations.
Arcila ME, Yu W, Syed M, et al. Establishment of immunoglobulin heavy (Igh) chain clonality testing by next-generation sequencing for routine characterization of b-cell and plasma cell neoplasms.
Yao Q, Bai Y, Orfao A, Chim CS. Standardized minimal residual disease detection by next-generation sequencing in multiple myeloma.
Invivoscribe is a specialist in standardized molecular assays for hematologic malignancies and offers advanced custom assay and biomarker solutions for oncology and precision medicine programs. Their custom capabilities include biomarker assay development on PCR and NGS platforms, from early concept through design, optimization, and validation, and the development of custom gene panels based on their MyAML®, MyHeme®, and MyMRD® technologies. In addition, Invivoscribe engineers bespoke positive and negative controls tailored to specific targets, platforms, and sensitivity requirements.
Invivoscribe also develops and manufactures clonality, MRD, and mutation assays together with associated bioinformatics software, and has extensive experience in companion diagnostics (CDx) development in partnership with pharmaceutical companies.
Beyond assay design, Invivoscribe provides integrated product development and manufacturing services that cover assay development for investigational use (IUO), research-use assays, CE marked IVDs, and CDx, along with regulatory and quality support. This enables assay developers and drug development teams to work with a single partner from early biomarker concept through to commercial ready kits and controls for clinical testing laboratories.
Through Bio Connect, customers in the Benelux can access Invivoscribe’s custom biomarker assay, gene panel, and control development solutions with local scientific and logistical support. Our team helps define your clinical and assay requirements, coordinates the custom development and manufacturing workflows with Invivoscribe, and ensures reliable delivery of high quality, fit for purpose assays and reagents tailored to your research, drug development, and molecular diagnostics workflows.
We gladly support you by keeping you updated on our latest products and developments
